Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 18, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of GBP14.59 per share, which was the price at which dividends were re-invested on October 5, 2006.
Material Changes
The document reports an increase in share interests for specific individuals following the re-investment of dividends paid on October 5, 2006. The specific increases are as follows:
- Dr M M Slaoui: 155 shares
- Mr R Bondy: 203 shares
- Mr M Dunoyer: 75 shares
- Mr D Learmouth: 30 shares
- Dr D Pulman: 115 shares
- Mr A Witty: 71 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory disclosure of director share transactions in compliance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares held by the listed directors post-transaction to assess concentration of ownership.
- Confirm the dividend payment date of October 5, 2006, and the re-investment mechanism details in the Annual Investment Plan.
- Check the share price of GBP14.59 against market data for October 5, 2006, to validate the transaction price.